Management of side-effects of anti-angiogenetic inhibitors in treating HCC
|
|
- Gavin Wilson
- 5 years ago
- Views:
Transcription
1 Management of side-effects of anti-angiogenetic inhibitors in treating HCC Massimo Di Maio Clinical Trials Unit National Cancer Institute, Napoli
2 BCLC staging system and treatment strategy Di Maio, Roma AISF 2011 HCC Stage 0 PST 0, Child Pugh A Stage A C PST 0 2, Child Pugh A B Stage D PST > 2, Child Pugh C Very early stage (0) 1 HCC < 2 cm Carcinoma in situ Early stage (A) 1 HCC or 3 nodules < 3 cm, PST 0 Intermediate stage (B) Multinodular, PST 0 Advanced stage (C) Portal invasion, N1, M1, PST 1 2 End stage (D) 1 HCC Portal pressure/ bilirubin Increased 3 nodules 3 cm Associated diseases Normal No Yes Resection Liver transplantation Curative treatments (30%) 5-year survival (40 70%) PEI/RFA TACE Sorafenib Randomized controlled trials (50%) Median survival months Symptomatic treatment (20%) Survival < 3 months Llovet JM, et al. J Natl Cancer Inst. 2008;100:
3 Sorafenib consistently increased overall survival in different patient populations SHARP 1 Asia Pacific Sorafenib (n = 299) Median OS: 10.7 months 1.00 Sorafenib (n = 150) Median OS: 6.5 months Survival probability Placebo (n = 303) Median OS: 7.9 months Survival probability Placebo (n = 76) Median OS: 4.2 months Months Months HR = 0.69 HR = 0.68 HR = hazard ratio; OS = overall survival; SHARP = Sorafenib Hepatocellular Carcinoma Assessment Randomized Protocol. 1. Llovet JM, et al. N Engl J Med. 2008;359: Cheng A, et al. Lancet Oncol. 2009;10:25-34.
4 The physician must have two special objects in view with regard to disease, namely, to do good or to do no harm Corpus Hippocraticum Epidemics Bk. I, Sect. 5, trans. Adams
5 Balance between efficacy and toxicity Systemic treatment of advanced HCC has a palliative aim Preserving and possibly improving, patients quality of life should be a primary goal of treatment YES! NO! Efficacy Toxicity Efficacy Toxicity
6 Managing patients with advanced HCC on systemic therapy Di Maio, Roma AISF 2011 Give correct information to patients before starting treatment Adopt preventive measures, when available YES! Careful monitoring during treatment Consider treatment interruption Consider dose reduction Evaluate and discuss risk/benefit ratio Efficacy Toxicity
7 Sorafenib is generally well tolerated Sorafenib is generally well tolerated and the majority of treatment-related AEs are grade 1 or 2 1,2 Common AEs include diarrhea, fatigue, skin rash / desquamation, and HFSR 1,2 These AEs may be managed using supportive measures, 3 which may reduce the need for dose modification WARNING: the majority of safety data from phase 3 trials are in Child Pugh A patients 4 AEs = adverse events; HFSR = hand foot skin reaction. 1. Llovet JM, et al. N Engl J Med. 2008;359: Cheng A-L, et al. Lancet Oncol. 2009;10: Wood LS, Manchen B. Clin J Oncol Nurs. 2007;11: Sorafenib EMEA SmPC. February 2010.
8 Daniele B, Di Maio M. Hot Topics Oncol. 2009;5:19-29.
9 Phase 2 trial: safety of sorafenib by Child Pugh class 1 Di Maio, Roma AISF 2011 Adverse events (%) Child Pugh A (n = 98) Child Pugh B (n = 38) All All serious Fatigue HFSR Diarrhea Bilirubin increase 18 40* Ascites Encephalopathy 2 11 Length of therapy 24.9 weeks 12.9 weeks Dose reductions 31% 21% *Potentially due to worsening cirrhosis 2 or may be related to sorafenib inhibition of UGT1A1 activity Abou-Alfa GK, et al. ASCO 2008; Chicago, IL, USA. 2. Zhu AX, Clark JW. Oncologist. 2009;14:67-9.
10 Sorafenib in patients with Child Pugh B liver dysfunction: GIDEON study Di Maio, Roma AISF 2011 Largest prospective study in unresectable HCC (uhcc) ever conducted, > 400 sites, > 40 countries, 5 designated regions: Asia Pacific, Europe, USA, Latin America, and Japan Eligibility criteria Unresectable HCC Primary endpoint Safety Candidate for systemic therapy Secondary endpoints Efficacy Decision to treat with sorafenib has been made Life expectancy of at least 8 weeks Signed informed consent Source Document Verification Recruitment FPFV: Jan 2009 (n = 3,000) Sorafenib 400 mg b.i.d. Duration of therapy Methods of patient evaluation, diagnosis, follow-up Influence of comorbidities on treatment and outcome Referral patterns First interim analysis: 511 patients enrolled from 140 sites 479 patients were valid for safety analysis Available at: NCT Accessed November Marrero J, et al. AASLD 2010, Boston, MA. Poster: 1721.
11 Treatment-emergent safety data: Child Pugh A and Child Pugh B patients n (%) Child Pugh A (< 7) subgroup n= 278 Child Pugh B (7 9) subgroup n= 134 AEs (all grades) 234 (84) 122 (91) AEs (grade 3/4) 71 (26)/14 (5) 42 (31)/10 (7) Drug-related AEs (all grades) 193 (69) 84 (63) Drug-related Aes (grade 3/4) 58 (21)/ 7(3) 27 (20)/ 4 (3) SAEs (all grades) 93 (33) 80 (60) Drug-related SAEs (all grades) a 28 (10) 22 (16) AEs resulting in permanent discontinuation of sorafenib b 69 (25) 53 (40) Deaths c 49 (18) 50 (37) a An SAE is defined as any AE occurring at any dose that results in any of the following outcomes: death; life-threatening hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect; medically important event; b Any AE; c treatment-emergent deaths occurring up to 30 days after last sorafenib dose. Marrero J, et al. AASLD 2010, Boston, MA. Poster 1721.
12 BOOST (B Child HCC patients Optimization Of Sorafenib Treatment) Di Maio, Roma AISF 2011 Patients - HCC advanced - Age >18 - PS Child B Stratification factors: - Child score (7, 8, 9) - CLIP score (1, 2-3, 4-5) - Age(<70, 70+) R A N D O M I Z E A B Best supportiv e care (BSC) Sorafenib 800 mg/d + BSC Primary endpoint: overall survival Sample size: 234 events, 320 patients EUDRACT NUMBER: AIFA code: FARM84SA2X
13 SHARP: drug-related AEs AE* Incidence by grade (%) p value for Sorafenib (n = 297) Placebo (n = 302) between-group comparison Any 3 4 Any 3 4 Any 3 or 4 Overall incidence Diarrhea < < Fatigue < HFSR < 1 0 < < Rash/desquamation Anorexia 14 < < Alopecia < N/A Nausea 11 < Weight loss < Pruritus < Dry skin N/A Pain, abdomen NOS Bleeding < Voice changes < N/A Vomiting Hypertension Dermatology, other < Liver dysfunction < 1 < *Assessed using the NCI-CTCAE (version 3.0) that occurred in at least 5% of patients in either arm. NOS = not otherwise specified. Llovet JM, et al. N Engl J Med. 2008;359:
14 AEs: prevention and management Patients should be informed to take preventive measures, where possible 1 be aware and report AEs as soon as possible 2,3 Patients alerted to possible AEs before beginning treatment may be more accepting of these symptoms 3 are more likely to stay on treatment Porta C, et al. Clin Exp Med. 2007;7: Wood L. Commun Oncol. 2006;3: Robert C, et al. Lancet Oncol. 2005;6: Autier J, et al. Arch Dermatol. 2008;144: Lacouture M, et al. The Oncologist. 2008;13:
15 Sorafenib: dose reductions Starting dose 400 mg (2 x 200 mg) administered orally (po) twice daily (b.i.d) First reduction 400 mg (2 x 200 mg) po every day Second reduction 400 mg (2 x 200 mg) po every two days Llovet JM, et al. N Engl J Med. 2008;359:
16 Hand foot skin reaction HFSR is a group of symptoms affecting the hands and/or feet 1,2 varying degrees of severity that tend to decrease during the course of therapy Common side effect of antiangiogenic therapies that usually occurs during the first few weeks of treatment 3 1. Moldawer N, Wood LS. Kidney Cancer J. 2006;4: Wood LS. Commun Oncol. 2006;3: Alexandrescu DT, et al. Clin Exp Dermatol. 2007;32:71-74.
17 Hand foot skin reaction: grading system* Di Maio, Roma AISF 2011 Grade 1 Clinical characteristics Numbness, dysesthesia, paresthesia, tingling, painless swelling, erythema, or discomfort of hands or feet, which does not disrupt patient s normal activities 2 One or more of: painful erythema, swelling, hyperkeratosis of the hands or feet, discomfort affecting the patient s normal activities 3 One or more of: moist desquamation, ulceration, blistering, hyperkeratosis, severe pain of the hands and feet, severe discomfort that causes the patient to be unable to work or perform daily activities *Modified from Common Terminology Criteria for Adverse Events, Version 3.0 (CTCAE), published August 9, 2006.
18 Hand foot skin reaction by grade Grade 1 Grade 2 Grade 3 Photos courtesy of Elizabeth Manchen, RN, MS, OCN.
19 Other skin reactions Maculopapular rash Facial rash Body rash Photos courtesy of Elizabeth Manchen, RN, MS, OCN.
20 Di Maio, Roma AISF 2011 HFSR prevention and management: counsel on the 3 C s
21 Di Maio, Roma AISF 2011 HFSR prevention and management: calluses Before sorafenib therapy check condition of hands and feet suggest a manicure/pedicure, when indicated recommend pumice stone for callus or rough spot removal y During sorafenib therapy pressure points items that rub, pinch, or create friction Wood L. Comm Oncol. 2006;3: Robert C, et al. Lancet Oncol. 2005;6:
22 Di Maio, Roma AISF 2011 HFSR prevention and management: creams Apply non-urea based creams liberally Apply urea-based creams sparingly and only to affected areas Avoid products with > 10% urea, as these may increase irritation Avoid systemic steroids Cetaphil Aveeno Udderly Smooth Gold Bond Norwegian Formula Eucerin Alpha-hydroxy acids (AHA) ~ 5% to 8% provide gentle chemical exfoliation apply liberally two times each day Wood L. Comm Oncol. 2006;3: Robert C, et al. Lancet Oncol. 2005;6:
23 Di Maio, Roma AISF 2011 HFSR prevention and management: cushions Protect tender areas Wear well-padded footwear Soak feet in tepid water and epsom salts Use socks/gloves to cover moisturizing creams Use insole cushions or inserts (e.g. silicon, gel) Wood L. Comm Oncol. 2006;3: Robert C, et al. Lancet Oncol. 2005;6:
24 HFSR - suggested managing of sorafenib Timing Dose Grade 1 No change No change Grade 2 1st Interruption until G0 1 No change 2nd Interruption until G0 1 Reduction (1 level) 3rd Interruption until G0 1 Reduction (2 levels) 4th Definitive stop - Grade 3 1st Interruption until G0 1 Reduction (1 level) 2nd Interruption until G0 1 Reduction (2 levels) 3rd Definitive stop - Llovet JM, et al. N Engl J Med. 2008;359:
25 Diarrhea Grade 1 Increase of < 4 stools/day over pretreatment Grade 2 Increase of 4 6 stools/day, or nocturnal stools 39% Grade 3 Increase of 7 stools/day or incontinence; or need for parenteral support for dehydration 8% Llovet JM, et al. N Engl J Med. 2008;359:
26 Diarrhea proposal for dose modification of sorafenib Timing Dose Grade 1 No change No change Grade 2 1st Interruption until G0 1 No change 2nd Interruption until G0 1 Reduction (1 level) 3rd Interruption until G0 1 Reduction (2 levels) 4th Definitive stop - Grade 3 1st Interruption until G0 1 Reduction (1 level) 2nd Interruption until G0 1 Reduction (2 levels) 3rd Definitive stop - Grade 4 Definitive stop -
27 Fatigue Grade 1 Increased fatigue over baseline, but not altering normal activities Grade 2 Moderate (e.g. decrease in Perfomance Status by 1 ECOG level or 20% Karnofsky or Lansky) or causing difficulty perfoming some activities 22% Grade 3 Severe (e.g. decrease in perfomance status by 2 ECOG levels or 40% Karnofsky or Lansky) or loss of ability to perform some activities 3% Llovet JM, et al. N Engl J Med. 2008;359: NCI-CTC version 2
28 Hauser W, et al. Clin Gastroenterol Hepatol. 2004;2:
29 Hypertension Hypertension most frequently occurs early in the course of treatment and is mostly amenable to management with standard antihypertensive therapy Blood pressure should be controlled before starting therapy Monitor blood pressure weekly during the first 6 weeks of therapy and continue thereafter Standard antihypertensives may be used In cases of severe or persistent hypertension that is not responsive to treatment, temporary or permanent discontinuation of sorafenib should be considered Wood L. Comm Oncol. 2006;3: Bhojani N, et al. Eur Urol. 2008;53:
30 Sorafenib in advanced HCC: when to stop? Di Maio, Roma AISF 2011 In the SHARP registrative trial: treatment continued until the occurrence of both radiologic progression (as defined by RECIST) and symptomatic progression (as defined by the Functional Assessment of Cancer Therapy Hepatobiliary Symptom Index 8 questionnaire) or the occurrence of either unacceptable adverse events or death Llovet JM, et al. N Engl J Med. 2008;359:
31 Sorafenib in advanced HCC: when to stop? Di Maio, Roma AISF 2011 In clinical practice (in the next single patient!): treatment should be continued as long as the risk/benefit ratio is favorable Efficacy Toxicity
32 A new model of evidence-based medicine Di Maio, Roma AISF 2011 Haynes RB, et al. BMJ. 2002;324:1350.
33 Summary Sorafenib significantly prolonged OS over placebo in advanced HCC Sorafenib therapy is recommended by various guidelines for patients with Child Pugh A or B status; however, caution is required when treating Child Pugh B patients with sorafenib Most AEs related to sorafenib are predictable and manageable Preventive measures can be taken to avoid dose reductions or treatment interruptions Treatment rarely needs to be permanently discontinued Good communication is vital among patients, clinicians, and nurses
34 Thanks for your attention! Bay of Naples from Sorrento
Supplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced
More informationNexavar in advanced HCC: a paradigm shift in clinical practice
Nexavar in advanced HCC: a paradigm shift in clinical practice Tim Greten Hanover Medical School, Germany Histopathological progression and molecular features of HCC Chronic liver disease Liver cirrhosis
More informationIl treatment plan nella terapia sistemica dell epatocarcinoma
Il treatment plan nella terapia sistemica dell epatocarcinoma M. Iavarone, MD PhD CRC A.M. e A. Migliavacca Center for the Study of Liver Disease Division of Gastroenterology and Hepatology Fondazione
More information12 AISF Special Conference Sorafenib: magnitude of benefit, side effects and stopping rules 9 years after approval
12 AISF Special Conference Sorafenib: magnitude of benefit, side effects and stopping rules 9 years after approval ARMANDO SANTORO Roma 10-6-2016 SORAFENIB APPROVAL 29 OCTOBER 2007 Marketing authorization
More informationSorafenib in HCC. Discussion points
Discussion points in Andrew X. Zhu, MD, PhD 214 CASL Meeting-Consensus, Controversies and Future Directions in -data from phase III trials ptimal Dosing Side effects and management strategies use in Child-Pugh
More information蕾莎瓦 Nexavar 臨床試驗資料 (HCC 肝細胞癌 )
蕾莎瓦 Nexavar 臨床試驗資料 (HCC 肝細胞癌 ) 1 Sorafenib Improves Survival in Hepatocellular Carcinoma: Results of a Phase III Randomized, -Controlled Trial Josep M. Llovet, Sergio Ricci, Vincenzo Mazzaferro, Philip
More informationObservational registry of sorafenib use in clinical practice across. Child-Pugh subgroups: The GIDEON study
Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study Jorge A. Marrero, Masatoshi Kudo, Alan P. Venook, Sheng-Long Ye, Jean-Pierre Bronowicki, Xiao-Ping
More informationCisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer. Valle J et al. N Engl J Med 2010;362(14):
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer Valle J et al. N Engl J Med 2010;362(14):1273-81. Introduction > Biliary tract cancers (BTC: cholangiocarcinoma, gall bladder cancer,
More informationRiunione Monotematica A.I.S.F The future of liver diseases. HEPATIC NEOPLASMS The challenge for new drugs
Riunione Monotematica A.I.S.F. 2016 The future of liver diseases Milan 13 th -15 th October 2016 Centro Congressi Fondazione Cariplo HEPATIC NEOPLASMS The challenge for new drugs Massimo Iavarone Gastroenterology
More informationStudy Objective and Design
Randomized, Open Label, Multicenter, Phase II Trial of Transcatheter Arterial Chemoembolization (TACE) Therapy in Combination with Sorafenib as Compared With TACE Alone in Patients with Hepatocellular
More informationBCCA Protocol Summary for Adjuvant Therapy of Colon Cancer using
BCCA Protocol Summary for Adjuvant Therapy of Colon Cancer using Capecitabine Protocol Code Tumour Group Contact Physician GIAJCAP Gastrointestinal GI Systemic Therapy ELIGIBILITY: Resected Stage III or
More informationBCCA Protocol Summary for Therapy of Metastatic Breast Cancer using Capecitabine
BCCA Protocol Summary for Therapy of Metastatic Breast Cancer using Capecitabine Protocol Code Tumour Group Contact Physician BRAVCAP Breast Dr. Susan Ellard ELIGIBILITY: First line treatment of metastatic
More informationBCCA Protocol Summary for Second line Treatment of Metastatic or Unresectable Pancreatic Adenocarcinoma Using Capecitabine
BCCA Protocol Summary for Second line Treatment of Metastatic or Unresectable Pancreatic Adenocarcinoma Using Capecitabine Protocol Code Tumour Group Contact Physician GIPAVCAP Gastrointestinal GI Systemic
More informationBARCELONA CLINIC LIVER CANCER (BCLC) STAGING AND TREATMENT STRATEGY FOR HEPATOCELLULAR CARCINOMA (HCC) 1
BARCELONA CLINIC LIVER CANCER (BCLC) STAGING AND TREATMENT STRATEGY FOR HEPATOCELLULAR CARCINOMA (HCC) 1 HCC Very early stage () Early stage (A) Intermediate stage (B) Advanced stage (C) Terminal stage
More informationHepatocellular Carcinoma HCC Updated November 2015 by: Dr. Mohammed Alghamdi (Medical Oncology Fellow, University of Calgary)
Hepatocellular Carcinoma HCC Updated November 2015 by: Dr. Mohammed Alghamdi (Medical Oncology Fellow, University of Calgary) Staff Reviewers: Dr. Yoo Joung Ko (Medical Oncologist, Sunnybrook Odette Cancer
More informationSorafenib for Egyptian patients with advanced hepatocellular carcinoma; single center experience
Journal of the Egyptian National Cancer Institute (2014) 26, 9 13 Cairo University Journal of the Egyptian National Cancer Institute www.nci.cu.adu.eg www.sciencedirect.com Original article Sorafenib for
More informationCelsion Symposium New Paradigms in HCC Staging: HKLC vs. BCLC Staging
Celsion Symposium New Paradigms in HCC Staging: HKLC vs. BCLC Staging Ronnie T.P. Poon, MBBS, MS, PhD Chair Professor of Hepatobiliary and Pancreatic Surgery Chief of Hepatobiliary and Pancreatic Surgery
More informationAdvances in percutaneous ablation and systemic therapies for hepatocellular carcinoma
Advances in percutaneous ablation and systemic therapies for hepatocellular carcinoma Paris Hepatology Congress 2019 Pierre Nahon Service d Hépatologie Hôpital Jean Verdier Bondy Université Paris 13 INSERM
More informationPREMEDICATIONS: Antiemetic protocol for highly emetogenic chemotherapy. May not need any antiemetic with
BCCA Protocol Summary for Palliative Therapy of Metastatic or Locally Advanced Gastric, Gastroesophageal Junction Adenocarcinoma, Esophageal Squamous Cell Carcinoma, or Anal Squamous Cell Carcinoma using
More information9th Paris Hepatitis Conference
9th Paris Hepatitis Conference Paris, 12 January 2016 Treatment of hepatocellular carcinoma: beyond international guidelines Massimo Colombo Chairman Department of Liver, Kidney, Lung and Bone Marrow Units
More informationLiver resection for HCC
8 th LIVER INTEREST GROUP Annual Meeting Cape Town 2017 Liver resection for HCC Jose Ramos University of the Witwatersrand Donald Gordon Medical Centre The liver is almost unique in that treatment of the
More informationBC Cancer Protocol Summary for Therapy of Adjuvant Breast Cancer using Capecitabine
BC Cancer Protocol Summary for Therapy of Adjuvant Breast Cancer using Capecitabine Protocol Code Tumour Group Contact Physician BRAJCAP Breast Dr. Stephen Chia ELIGIBILITY: Adjuvant breast cancer therapy
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationHCC with Intrahepatic Portal vein Tumour Should Be Treated by Systemic Therapy Rather Than Transarterial Therapy (Pros)
HCC with Intrahepatic Portal vein Tumour Should Be Treated by Systemic Therapy Rather Than Transarterial Therapy (Pros) Yi-Hsiang Huang, MD, Ph.D. Professor, Division of Gastroenterology & Hepatology,
More informationBCCA Protocol Summary for Curative Combined Modality Therapy for Carcinoma of the Anal Canal Using Mitomycin, Capecitabine and Radiation Therapy
BCCA Protocol Summary for Curative Combined Modality Therapy for Carcinoma of the Anal Canal Using Mitomycin, and Radiation Therapy Protocol Code: Tumour Group: Contact Physician: GICART Gastrointestinal
More informationManagement of HepatoCellular Carcinoma
9th Symposium GIC St Louis - 2010 Management of HepatoCellular Carcinoma Overview Pierre A. Clavien, MD, PhD Department of Surgery University Hospital Zurich Zurich, Switzerland Hepatocellular carcinoma
More informationA) PUBLIC HEALTH B) PRESENTATION & DIAGNOSIS
Hepatocellular Carcinoma HCC Updated November 2015 by: Dr. Mohammed Alghamdi (Medical Oncology Fellow, University of Calgary), April 2017 by Dr. Jenny Ko (Medical Oncologist, Abbotsford Centre, BC Cancer
More informationAdvances in Systemic Therapy Hepatocellular Carcinoma (HCC) Dr ZEE Ying Kiat HASLD Conference Ho Chi Minh City, 18 December 2016
Advances in Systemic Therapy for Hepatocellular Carcinoma (HCC) Dr ZEE Ying Kiat HASLD Conference Ho Chi Minh City, 18 December 2016 Scope Background Staging and treatment strategies Current systemic therapy
More informationMultikinase inhibitors: Multikinase inhibitors: Regorafenib skin toxicity. Cutaneous side effects of multikinase-inhibitors and their management
TARGETED THERAPIES AND THEIR CUTANEOUS TOXICITIES Brussels, 14/1/2017 Cutaneous side effects of multikinase-inhibitors and their management Siegfried Segaert Dermatology Dept. Uinversity Hospital Leuven
More informationBCCA Protocol Summary for Combined Modality Adjuvant Therapy for High Risk Rectal Carcinoma using Capecitabine and Radiation Therapy
BCCA Protocol Summary for Combined Modality Adjuvant Therapy for High Risk Rectal Carcinoma using Capecitabine and Radiation Therapy Protocol Code: Tumour Group: Contact Physician: GIRCRT Gastrointestinal
More informationHCC: Epidemiology. Update on treatment of advanced hepatocellular carcinoma. Incidence of HCC is increasing
Update on treatment of advanced hepatocellular carcinoma Jean-Luc Raoul Centre E Marquis Rennes, Brittany France HCC: Epidemiology Europe - USA: C virus, alcohol obesity, iron Europe: 4 deaths / year 6
More informationHepatocellular Carcinoma (HCC): Who Should be Screened and How Do We Treat? Tom Vorpahl MSN, RN, ACNP-BC
Hepatocellular Carcinoma (HCC): Who Should be Screened and How Do We Treat? Tom Vorpahl MSN, RN, ACNP-BC Objectives Identify patient risk factors for hepatocellular carcinoma (HCC) Describe strategies
More informationCarcinoma de Tiroide: Teràpies Diana
Carcinoma de Tiroide: Teràpies Diana Jaume Capdevila, MD GI and Endocrine Tumor Unit Vall d Hebron University Hospital Developmental Therapeutics Unit Vall d Hebron Institute of Oncology THYROID CANCER:
More informationFor personal use only
Sirtex Medical Limited SARAH Clinical Study Results Investor Presentation Nigel Lange, Interim CEO Dr David N. Cade, CMO 24 April 2017 SIR-Spheres is a registered trademark of Sirtex SIR-Spheres Pty Ltd
More informationSorafenib for Advanced Hepatocellular Carcinoma
CED-SOS Advice Report 7 ARCHIVED 2012 Sorafenib for Advanced Hepatocellular Carcinoma J. Knox, R. Cosby, K. Chan, and M. Sherman A Quality Initiative of the Program in Evidence-Based Care (PEBC), Cancer
More informationBCCA Protocol Summary for Palliative Therapy for Metastatic Breast Cancer Using Trastuzumab (HERCEPTIN) and Capecitabine
BCCA Protocol Summary for Palliative Therapy for Metastatic Breast Cancer Using Trastuzumab (HERCEPTIN) and Capecitabine Protocol Code Tumour Group Contact Physician UBRAVTCAP Breast Dr. Stephen Chia ELIGIBILITY:
More informationSurveillance for Hepatocellular Carcinoma
Surveillance for Hepatocellular Carcinoma Marion G. Peters, MD John V. Carbone, MD, Endowed Chair Professor of Medicine Chief of Hepatology Research University of California San Francisco Recorded on April
More informationNCCP Chemotherapy Regimen
INDICATIONS FOR USE: SORAfenib Therapy INDICATION ICD10 Regimen Code Treatment of hepatocellular carcinoma (HCC). C22 00294a CDS C64 00294b CDS Treatment of patients with advanced renal cell carcinoma
More informationSorafenib for the treatment of advanced hepatocellular carcinoma
DOI: 10.3310/hta14suppl1/03 Health Technology Assessment 2010; Vol. 14: Suppl. 1 Sorafenib for the treatment of advanced hepatocellular carcinoma M Connock, 1 J Round, 2 S Bayliss, 1 S Tubeuf, 2 W Greenheld
More information3/22/2017. I will be discussing off label/investigational use of tivantinib for hepatocellular carcinoma.
Grant/Research Support - AbbVie, Conatus, Hologic, Intercept, Genfit, Gilead, Mallinckrodt, Merck, Salix, Shire, Vital Therapies Consultant AbbVie, Gilead, Merck Member, Scientific Advisory Board Vital
More informationNCCP Chemotherapy Regimen
INDICATIONS FOR USE: Capecitabine Monotherapy Regimen *Reimbursement INDICATION ICD10 Code Indicator Treatment of patients with locally advanced or metastatic breast cancer C50 00216a CDS Treatment of
More informationHepatocellular Carcinoma: A major global health problem. David L. Wood, MD Interventional Radiology Banner Good Samaritan Medical Center
Hepatocellular Carcinoma: A major global health problem David L. Wood, MD Interventional Radiology Banner Good Samaritan Medical Center Hepatocellular Carcinoma WORLDWIDE The #2 Cancer Killer Overall cancer
More informationHepatocellular Carcinoma. Markus Heim Basel
Hepatocellular Carcinoma Markus Heim Basel Outline 1. Epidemiology 2. Surveillance 3. (Diagnosis) 4. Staging 5. Treatment Epidemiology of HCC Worldwide, liver cancer is the sixth most common cancer (749
More informationHepatocellular carcinoma: from guidelines to individualized treatment
AISF 2012 Rome, 22-24 February 2012 Hepatocellular carcinoma: from guidelines to individualized treatment A.D. 1088 Luigi Bolondi Professor of Medicine, Chairman Department of Digestive Diseases and Internal
More information6/16/2016. Treating Hepatocellular Carcinoma: Deciphering the Clinical Data. Liver Regeneration. Liver Regeneration
Treating : Deciphering the Clinical Data Derek DuBay, MD Associate Professor of Surgery Director of Liver Transplant Liver Transplant and Hepatobiliary Surgery UAB Department of Surgery Liver Regeneration
More informationQUANDO LA TERAPIA MEDICA
IL NODULO EATICO dalla diagnosi.. alla terapia Sala Conferenze, Biblioteca "Rosanna Benzi" Genova Voltri 21 Settembre 2013 QUANDO LA TERAIA MEDICA Dott. Gianfranco ercario U.O.S. di Gastroenterologia OEI
More informationΗπατοκυτταρικός Καρκίνος Συστηματική Θεραπεία. Θωμάς Μακατσώρης Επίκ. Καθ. Παθολογίας-Ογκολογίας Ιατρική Σχολή Πανεπιστημίου Πατρών 11/5/2018
Ηπατοκυτταρικός Καρκίνος Συστηματική Θεραπεία Θωμάς Μακατσώρης Επίκ. Καθ. Παθολογίας-Ογκολογίας Ιατρική Σχολή Πανεπιστημίου Πατρών 11/5/2018 Advisory Board Disclosures Roche, Boeringer, Sanofi, Astra Zeneca,
More informationPercutaneous ablation: indications, techniques and results
Percutaneous ablation: indications, techniques and results Giovan Giuseppe Di Costanzo Dipartimento dei Trapianti UOSC Epatologia AORN A Cardarelli - Napoli Treatment algorithm EASL, EORTC guidelines HCC
More informationClinical Staging for Hepatocellular Carcinoma: Eastern Perspectives. Osamu Yokosuka, M.D. Graduate School of Medicine, Chiba University, Chiba, Japan
Clinical Staging for Hepatocellular Carcinoma: Eastern Perspectives Osamu Yokosuka, M.D. Graduate School of Medicine, Chiba University, Chiba, Japan Why is staging system important? Cancer stage can be
More informationWHAT IS THE BEST APPROACH FOR TRANS-ARTERIAL THERAPY IN HCC?
WHAT IS THE BEST APPROACH FOR TRANS-ARTERIAL THERAPY IN HCC? Dr. Alexander Kim Chief, Vascular and Interventional Radiology, Medstar Georgetown University Hospital, USA DISCLAIMER Please note: The views
More informationIS THERE A DIFFERENCE IN LIVER CANCER RATES IN PATIENTS WHO RECEIVE TREATMENT FOR HEPATITIS?
IS THERE A DIFFERENCE IN LIVER CANCER RATES IN PATIENTS WHO RECEIVE TREATMENT FOR HEPATITIS? Dr. Sammy Saab David Geffen School of Medicine, Los Angeles, USA April 2018 DISCLAIMER Please note: The views
More informationSIRT for Intermediate and Advanced HCC
Pamplona, junio de 2008 SIRT for Intermediate and Advanced HCC Bruno Sangro Clínica Universidad de Navarra. CIBERehd. Pamplona, Spain 90 Y-RE MRI SPECT FUSION 90 Y-RE = Yttrium-90 radioembolization Sangro
More informationTREATMENT ALGORITHM FOR HEPATOCELLULAR CARCINOMA
HCC treatment : A permanent challenge! TREATMENT ALGORITHM FOR HEPATOCELLULAR CARCINOMA Michel Ducreux, MD, PhD Paul Brousse University Hospital Gustave Roussy Institute Villejuif, FRANCE A low level of
More informationUnmet needs in intermediate HCC. Korea University Guro Hospital Ji Hoon Kim
Unmet needs in intermediate HCC Korea University Guro Hospital Ji Hoon Kim BCLC HCC Stage 0 PST 0, Child Pugh A Stage A C PST 0 2, Child Pugh A B Stage D PST > 2, Child Pugh C Very early stage (0) 1 HCC
More informationReal-Life Experience of Sorafenib Treatment for Hepatocellular Carcinoma in Korea: From GIDEON Data
pissn 1598-2998, eissn 2005-9256 Cancer Res Treat. 2016;48(4):1243-1252 Original Article http://dx.doi.org/10.4143/crt.2015.278 Open Access Real-Life Experience of Sorafenib Treatment for Hepatocellular
More informationYour Guide. A resource to provide you with information about your therapy
Your Guide to A resource to provide you with information about your therapy Please see Important Safety Information on pages 4 through 6 and accompanying full Prescribing Information. Pictures are for
More informationReDOS Trial Background
Regorafenib Dose Optimization Study (ReDos) A Phase II Randomized Study of Lower Dose Regorafenib Compared to Standard Dose Regorafenib in Patients With Refractory Metastatic Colorectal Cancer (mcrc) Abstract
More informationHepatozelluläres Karzinom und Cholangiokarzinom was kommt nach Sorafenib? Stefan Kubicka
Hepatozelluläres Karzinom und Cholangiokarzinom was kommt nach Sorafenib? Stefan Kubicka SHARP 1 versus Asia-Pacific-Study 2 SHARP S:299/P:303 Asia-Pacific S:150/P:76 End point HR p-value HR p-value OS
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationCurrent Concepts in the Treatment of HCC
Falk Symposium 167 Current Concepts in the Treatment of HCC Peter R. Galle I. Medical Department Johannes Gutenberg-University Mainz Germany Liver cancer: sixth most common cancer worldwide Most common
More informationNew Therapies in HCC Bruno Sangro Clínica Universidad de Navarra. IdISNA. CIBERehd. Pamplona, Spain
New Therapies in HCC Bruno Sangro Clínica Universidad de Navarra. IdISNA. CIBERehd. Pamplona, Spain PHC 2018 - www.aphc.info EASL-EORTC Guidelines EASL EORTC Guidelines. J Hepatol. 2012;56:908-43. Systemic
More informationRETHINKING OUR APPROACH TO INTERMEDIATE-SIZE HCC
SATELLITE SYMPOSIUM Emerging Horizons in HCC: From Palliation to Cure RETHINKING OUR APPROACH TO INTERMEDIATE-SIZE HCC Professor Riccardo Lencioni, MD, FSIR, EBIR University of Pisa School of Medicine,
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationScottish Medicines Consortium
Scottish Medicines Consortium sorafenib 200mg tablets (Nexavar ) (No. 321/06) Bayer Plc 6 October 2006 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises
More informationMETRIC Study Key Eligibility Criteria
The METRIC Study METRIC Study Key Eligibility Criteria The pivotal METRIC Study is evaluating glembatumumab vedotin in patients with gpnmb overexpressing metastatic triple-negative breast cancer (TNBC).
More informationOptimal management of HCC: in Asia
Optimal management of HCC: in Asia Kwang-Hyub Han, MD Department of Internal Medicine, Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea Newly diagnosed HCC : > 70% occur
More informationTREATMENT FOR HCC AND CHOLANGIOCARCINOMA. Shawn Pelletier, MD
TREATMENT FOR HCC AND CHOLANGIOCARCINOMA Shawn Pelletier, MD Treatment for HCC Treatment strategies Curative first line therapy Thermal ablation vs Resection vs Transplant Other first line therapies TACE
More informationAddictive Benefit of Transarterial Chemoembolization and Sorafenib in Treating Advanced Stage Hepatocelluar Carcinoma: Propensity Analysis
Addictive Benefit of Transarterial Chemoembolization and Sorafenib in Treating Advanced Stage Hepatocelluar Carcinoma: Propensity Analysis Gwang Hyeon Choi, Ju Hyun Shim*, Min-Joo Kim, Min-Hee Ryu, Baek-Yeol
More informationHepatocellular Carcinoma
Hepatocellular Carcinoma Ghassan K. Abou-Alfa Memorial Sloan Kettering Cancer Center Great Debates & Updates in GI Malignancies New York, NY March 28, 2015 Epidemiology Scoring and staging Agenda Curative
More informationSorafenib (so-ra-fe-nib) is a drug that is used to treat many types of cancer. It is a tablet that you take by mouth.
For the Patient: Other names: Sorafenib NEXAVAR Sorafenib (so-ra-fe-nib) is a drug that is used to treat many types of cancer. It is a tablet that you take by mouth. A blood test may be taken before each
More informationUPDATE TO THE MANAGEMENT OF PATIENTS WITH HCC HCA
UPDATE TO THE MANAGEMENT OF PATIENTS WITH HCC HUSSEIN K. MOHAMED MD, FACS. Transplant and Hepato-biliary Surgery Largo Medical Center HCA DISCLOSURE I have no financial relationship(s) relevant to the
More informationDOSING AND INFORMATION GUIDE LEAPS AHEAD
DOSING AND INFORMATION GUIDE In patients with WT RAS* mcrc 1 VECTIBIX (panitumumab) LEAPS AHEAD 5.6-month increase in median OS with FOLFOX vs FOLFOX alone 1 Spot the difference. CHOOSE VECTIBIX PRIME
More informationMEET ROY*: A PATIENT WITH LIVER-LIMITED mcrc
MEET ROY*: A PATIENT WITH LIVER-LIMITED mcrc * A hypothetical case study of a patient eligible for first-line mcrc therapy. mcrc = metastatic colorectal cancer. WHAT CLINICAL CHARACTERISTICS AFFECT YOUR
More informationHepatocellular Carcinoma
Hepatocellular Carcinoma Luis S. Marsano, MD Professor of Medicine Division of Gastroenterology, Hepatology, & Nutrition University of Louisville & Louisville VAMC 2010 Magnitude of the Problem 95% of
More informationTRANSPARENCY COMMITTEE OPINION. 5 March 2008
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 5 March 2008 NEXAVAR 200 mg, film-coated tablet B/112 (CIP: 376 137-2) Applicant: BAYER SANTE sorafenib List I Medicinal
More informationSEQUENCING OF HCC TREATMENT. Dr. Amit G. Singal Medical Director, UT Southwestern Medical Center, USA
SEQUENCING OF HCC TREATMENT Dr. Amit G. Singal Medical Director, UT Southwestern Medical Center, USA February 2018 DISCLAIMER Please note: The views expressed within this presentation are the personal
More informationPrimary Endpoint The primary endpoint is overall survival, measured as the time in weeks from randomization to date of death due to any cause.
CASE STUDY Randomized, Double-Blind, Phase III Trial of NES-822 plus AMO-1002 vs. AMO-1002 alone as first-line therapy in patients with advanced pancreatic cancer This is a multicenter, randomized Phase
More informationDisclosure. Speaker name: Prof. Maciej Pech I have the following potential conflicts of interest to report:
Disclosure Speaker name: Prof. Maciej Pech I have the following potential conflicts of interest to report: Consulting Employment in industry Stockholder of a healthcare company Owner of a healthcare company
More informationABOUT THIS MEDICATION
For the Patient: UHNOTVAN Other Names: Therapy for Medullary Thyroid Cancer using Vandetanib HN = Head and Neck (tumour group) OT = Other (includes Thyroid) VAN = VANdetanib ABOUT THIS MEDICATION What
More informationBenefit-Risk Summary of Regorafenib for the Treatment of Patients with Advanced Hepatocellular Carcinoma That Has Progressed on Sorafenib
Regulatory Issues: FDA Benefit-Risk Summary of Regorafenib for the Treatment of Patients with Advanced Hepatocellular Carcinoma That Has Progressed on Sorafenib LORRAINE PELOSOF, STEVEN LEMERY, SANDRA
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the
More informationAvailable at American Society of Clinical Oncology: 3
Addition of Tarceva (erlotinib) to Nexavar (sorafenib) did not Provide Additional Benefit to Patients with Unresectable Liver Cancer Versus Nexavar alone in Phase 3 Trial Wayne, NJ, South San Francisco,
More informationORIGINAL PAPER. Introduction. R. Lencioni, 1 J. Marrero, 2 A. Venook, 3 S.-L. Ye, 4 M. Kudo 5
ORIGINAL PAPER Design and rationale for the non-interventional Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafenib (GIDEON) study R. Lencioni,
More informationORIGINAL PAPER. Introduction
ORIGINAL PAPER First interim analysis of the GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafenib) non-interventional study R. Lencioni,
More informationSafety and efficacy of sorafenib in Japanese patients with hepatocellular carcinoma in clinical practice: a subgroup analysis of GIDEON
J Gastroenterol (2016) 51:1150 1160 DOI 10.1007/s00535-016-1204-2 ORIGINAL ARTICLE LIVER, PANCREAS, AND BILIARY TRACT Safety and efficacy of sorafenib in Japanese patients with hepatocellular carcinoma
More informationThe Current Champion: Angiogenesis inhibitors
The Current Champion: Angiogenesis inhibitors Baek-Yeol RYOO University of Ulsan College of Medicine ASAN Medical Center Dept. of Oncology Seoul, Korea Survival probability Sorafenib: Overall Survival
More informationRIBOCICLIB EN PRIMERA LINEA DE TRATAMIENTO. Dra. Elena Aguirre H.U. Miguel Servet
RIBOCICLIB EN PRIMERA LINEA DE TRATAMIENTO Dra. Elena Aguirre H.U. Miguel Servet INTRODUCTION ADVANCED BREAST CANCER HR+/HER2- YES Consider Chemo VISCERAL CRISIS? NO Endocrine Therapy X3 Toxicity Progresive
More informationin Hepatocellular Carcinoma
in Hepatocellular Carcinoma The following summarises the key data supporting the use of SIR-Spheres Y-90 resin microspheres in the treatment of primary liver cancer due to hepatocellular carcinoma (HCC):
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More informationSurgical management of HCC. Evangelos Prassas Hepatobiliary and Pancreatic Surgery / Liver Transplantation Kings College Hospital / London
Surgical management of HCC Evangelos Prassas Hepatobiliary and Pancreatic Surgery / Liver Transplantation Kings College Hospital / London Global distribution of HCC and staging systems WEST 1. Italy (Milan,
More informationSafety Considerations and Side Effect Management with Tyverb (Lapatinib)
Safety Considerations and Side Effect Management with Tyverb (Lapatinib) Prescribing information can be found at the end of the presentation Date of prep: 19-Sep-2011 UK/LPD/0226a/11 HER2 (ErbB2)-positive
More informationDrug Dose BC Cancer Administration Guidelines oxaliplatin 130 mg/m 2 IV in 500 ml* of D5W over 2 hours capecitabine 1000 mg/m 2 BID PO x 14 days
BC Cancer Protocol Summary for Adjuvant Chemotherapy of Gastric Cancer Patients with D2 Resection (node negative) or Ineligible for Adjuvant Chemoradiation Using Oxaliplatin and Capecitabine Protocol Code:
More informationRevised: 12/2017 FULL PRESCRIBING INFORMATION: CONTENTS* 1 INDICATIONS AND USAGE
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use NEXAVAR safely and effectively. See full prescribing information for NEXAVAR. NEXAVAR (sorafenib)
More informationTargeted Therapies in Metastatic Colorectal Cancer: An Update
Targeted Therapies in Metastatic Colorectal Cancer: An Update ASCO 2007: Targeted Therapies in Metastatic Colorectal Cancer: An Update Bevacizumab is effective in combination with XELOX or FOLFOX-4 Bevacizumab
More informationAE Toxicity Grading for Transplant Patients
AE Toxicity Grading for Transplant Patients Marcie Tomblyn, MD, MS Associate Member Director, BMT Clinical Research Moffitt Cancer Center Objectives Why do we care????? Toxicity vs Adverse Event vs Serious
More informationSorafenib Side effects and dose adjustment SORAMIC
Sorafenib Side effects and dose adjustment 1 Adverse events: prevention and management as key Patients should be informed to: Take preventive measures, where possible Be aware and report AEs as soon as
More informationManagement of advanced Hepatocellular carcinoma
Management of advanced Hepatocellular carcinoma V Di Martino* Acknowledgements to T Thevenot *Advisory board/lectures/travel facilities: Case report (1) Mr T. Philippe 55 yrs old Past IV drug user (1985)
More informationImmunoconjugates in Both the Adjuvant and Metastatic Setting
Immunoconjugates in Both the Adjuvant and Metastatic Setting Mark Pegram, M.D. Director, Stanford Breast Oncology Program Co-Director, Molecular Therapeutics Program Trastuzumab Treatment of Breast Tumor
More informationLiver transplantation: Hepatocellular carcinoma
Liver transplantation: Hepatocellular carcinoma Alejandro Forner BCLC Group. Liver Unit. Hospital Clínic. University of Barcelona 18 de marzo 2015 3r Curso Práctico de Transplante de Órganos Sólidos Barcelona
More information